董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eugene Williams | 男 | Director and Chairman | 65 | 22.67万美元 | 1.64 | 2025-10-22 |
| Neil Cashman | 男 | Chief Scientific Officer & Director | 73 | 51.59万美元 | 1.91 | 2025-10-22 |
| Patrick Kirwin | 男 | Director | 68 | 5.94万美元 | 1.25 | 2025-10-22 |
| Josh Mandel Brehm | 男 | Director | 42 | 6.34万美元 | 0.17 | 2025-10-22 |
| Neil K. Warma | 男 | Chief Executive Officer and Director | 62 | 83.02万美元 | 5.46 | 2025-10-22 |
| Maggie Shafmaster | 女 | Lead Independent Director | 66 | 5.79万美元 | 未持股 | 2025-10-22 |
| Slanix Paul Alex | 男 | Director | -- | 0.77万美元 | 0.05 | 2025-10-22 |
| William Wyman | 男 | Director | 87 | 7.19万美元 | 0.47 | 2025-10-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel E. Geffken | 男 | Chief Financial Officer | 68 | 未披露 | 未持股 | 2025-10-22 |
| Neil Cashman | 男 | Chief Scientific Officer & Director | 73 | 51.59万美元 | 1.91 | 2025-10-22 |
| Larry Altstiel | 男 | Chief Medical Officer | 75 | 54.42万美元 | 未持股 | 2025-10-22 |
| Johanne Kaplan | 女 | Chief Development Officer | 65 | 58.19万美元 | 1.18 | 2025-10-22 |
| Neil K. Warma | 男 | Chief Executive Officer and Director | 62 | 83.02万美元 | 5.46 | 2025-10-22 |
董事简历
中英对照 | 中文 | 英文- Eugene Williams
-
Eugene Williams，自2022年9月起担任董事长。从2021年10月到2022年9月，他担任公司董事长兼首席执行官。在此之前，Williams先生自2015年7月起担任公司董事长。此前，他曾担任Akashi （f/k/a DART Therapeutics, Inc.）的董事长兼首席执行官（2010年6月至2014年1月）。此前，他是Genzyme的高级执行官，在那里他在药物开发、商业化和许可方面负有广泛的管理责任。他毕业于哈佛学院（Harvard College），获得经济学学士学位，并获得哈佛商学院（Harvard Business School）工商管理硕士学位。
Eugene Williams,served as Chairman of the Company since July 2015. Prior, Mr. Williams currently serves as CEO of Autoimmunity BioSolutions (ABS) since November 2024, a preclinical stage biotech developing therapeutics and diagnostics in autoimmune disease, and as the SVP Strategy at Acta Pharmaceuticals since November 2022. Acta is developing small molecule therapies and natural supplements for Alzheimer's Disease. Mr. Williams also served as Chairman and Chief Executive Officer of Akashi (f/k/a DART Therapeutics, Inc.) from June 2010 to January 2014. Previously Mr. Williams was a senior executive at Genzyme, where he had broad management responsibilities in drug development, commercialization, and licensing. Mr. Williams graduated from Harvard College with a Bachelor of Arts degree in Economics and earned a Master of Business Administration from Harvard Business School. - Eugene Williams，自2022年9月起担任董事长。从2021年10月到2022年9月，他担任公司董事长兼首席执行官。在此之前，Williams先生自2015年7月起担任公司董事长。此前，他曾担任Akashi （f/k/a DART Therapeutics, Inc.）的董事长兼首席执行官（2010年6月至2014年1月）。此前，他是Genzyme的高级执行官，在那里他在药物开发、商业化和许可方面负有广泛的管理责任。他毕业于哈佛学院（Harvard College），获得经济学学士学位，并获得哈佛商学院（Harvard Business School）工商管理硕士学位。
- Eugene Williams,served as Chairman of the Company since July 2015. Prior, Mr. Williams currently serves as CEO of Autoimmunity BioSolutions (ABS) since November 2024, a preclinical stage biotech developing therapeutics and diagnostics in autoimmune disease, and as the SVP Strategy at Acta Pharmaceuticals since November 2022. Acta is developing small molecule therapies and natural supplements for Alzheimer's Disease. Mr. Williams also served as Chairman and Chief Executive Officer of Akashi (f/k/a DART Therapeutics, Inc.) from June 2010 to January 2014. Previously Mr. Williams was a senior executive at Genzyme, where he had broad management responsibilities in drug development, commercialization, and licensing. Mr. Williams graduated from Harvard College with a Bachelor of Arts degree in Economics and earned a Master of Business Administration from Harvard Business School.
- Neil Cashman
-
Neil Cashman，CSO兼董事Cashman博士分别自2004年5月和2010年6月起担任CSO和公司董事。卡什曼博士从2005年7月起担任英国不列颠哥伦比亚大学教授，直到2022年2月1日成为荣休教授，成为该公司的全职雇员。他还曾于2005年至2019年在加拿大不列颠哥伦比亚大学担任神经退行性疾病和蛋白质错误折叠疾病的加拿大研究主席。2005年7月至2022年1月，他还担任温哥华总医院ALS诊所主任。卡什曼博士在鲍登学院获得物理学学士学位，在马萨诸塞大学医学院获得医学学位。卡什曼博士曾在芝加哥大学医院和诊所担任神经病学住院医师。我们相信Cashman博士在ProMIS Neurosciences Inc.公司的历史经验以及他的专业经验使他有资格担任Promis Neurosciences公司的董事会成员。
Neil Cashman,served as a Professor at the UBC from July 2005 until he became Professor Emeritus as of February 1, 2022, when he became a full-time employee of the Company. He has also served as the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases at UBC from 2005 to 2019. He was also director of the ALS Clinic at Vancouver General Hospital from July 2005 to January 2022. Dr. Cashman earned a Bachelor of Arts degree in Physics from Bowdoin College and a Medical Degree from the University of Massachusetts Medical School. Dr. Cashman served his residency in neurology with the University of Chicago Hospitals & Clinics. - Neil Cashman，CSO兼董事Cashman博士分别自2004年5月和2010年6月起担任CSO和公司董事。卡什曼博士从2005年7月起担任英国不列颠哥伦比亚大学教授，直到2022年2月1日成为荣休教授，成为该公司的全职雇员。他还曾于2005年至2019年在加拿大不列颠哥伦比亚大学担任神经退行性疾病和蛋白质错误折叠疾病的加拿大研究主席。2005年7月至2022年1月，他还担任温哥华总医院ALS诊所主任。卡什曼博士在鲍登学院获得物理学学士学位，在马萨诸塞大学医学院获得医学学位。卡什曼博士曾在芝加哥大学医院和诊所担任神经病学住院医师。我们相信Cashman博士在ProMIS Neurosciences Inc.公司的历史经验以及他的专业经验使他有资格担任Promis Neurosciences公司的董事会成员。
- Neil Cashman,served as a Professor at the UBC from July 2005 until he became Professor Emeritus as of February 1, 2022, when he became a full-time employee of the Company. He has also served as the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases at UBC from 2005 to 2019. He was also director of the ALS Clinic at Vancouver General Hospital from July 2005 to January 2022. Dr. Cashman earned a Bachelor of Arts degree in Physics from Bowdoin College and a Medical Degree from the University of Massachusetts Medical School. Dr. Cashman served his residency in neurology with the University of Chicago Hospitals & Clinics.
- Patrick Kirwin
-
Patrick Kirwin，董事Kirwin先生自2015年6月起担任本公司董事。柯文是柯文律师事务所的高级合伙人。Kirwin先生在阿尔伯塔大学获得经济学学士学位，在多伦多大学法学院获得法学博士学位。我们相信，Kirwin先生的专业经验使他有资格担任Promis Neurosciences Inc.的董事会成员。
Patrick Kirwin,is senior partner at the law firm Kirwin LLP. Mr. Kirwin earned a Bachelor of Arts degree in Economics from the University of Alberta and a Juris Doctor from the University of Toronto Law School. - Patrick Kirwin，董事Kirwin先生自2015年6月起担任本公司董事。柯文是柯文律师事务所的高级合伙人。Kirwin先生在阿尔伯塔大学获得经济学学士学位，在多伦多大学法学院获得法学博士学位。我们相信，Kirwin先生的专业经验使他有资格担任Promis Neurosciences Inc.的董事会成员。
- Patrick Kirwin,is senior partner at the law firm Kirwin LLP. Mr. Kirwin earned a Bachelor of Arts degree in Economics from the University of Alberta and a Juris Doctor from the University of Toronto Law School.
- Josh Mandel Brehm
-
Josh Mandel Brehm，董事Mandel-Brehm先生自2021年9月起担任本公司董事。Mandel-Brehm先生自2017年5月起担任CAMP4 Therapeutics Corporation总裁兼首席执行官，并担任Polaris Partners的企业家合伙人。在2017年5月之前，Mandel-Brehm先生于2013年5月至2017年5月在渤健公司的业务发展部门任职。自2019年10月以来，他还是Vico Therapeutics B.V.的创始人和董事会成员。Mandel-Brehm先生在圣路易斯华盛顿大学获得生物学学士学位，在密歇根大学获得工商管理硕士学位。我们相信Mandel-Brehm先生在生物技术行业的经验使他有资格担任Promis Neurosciences Inc.的董事会成员。
Josh Mandel Brehm,has served as President and Chief Executive Officer of CAMP4 Therapeutics Corporation since May 2017 and as entrepreneur partner with Polaris Partners. Prior to May 2017, Mr. Mandel-Brehm served in business development for Biogen Corporation from May 2013 to May 2017. He has also been a founder and board member for Vico Therapeutics B.V. since October 2019. Mr. Mandel-Brehm earned a Bachelor of Arts degree in Biology from Washington University in St. Louis and a Master of Business Administration from the University of Michigan. - Josh Mandel Brehm，董事Mandel-Brehm先生自2021年9月起担任本公司董事。Mandel-Brehm先生自2017年5月起担任CAMP4 Therapeutics Corporation总裁兼首席执行官，并担任Polaris Partners的企业家合伙人。在2017年5月之前，Mandel-Brehm先生于2013年5月至2017年5月在渤健公司的业务发展部门任职。自2019年10月以来，他还是Vico Therapeutics B.V.的创始人和董事会成员。Mandel-Brehm先生在圣路易斯华盛顿大学获得生物学学士学位，在密歇根大学获得工商管理硕士学位。我们相信Mandel-Brehm先生在生物技术行业的经验使他有资格担任Promis Neurosciences Inc.的董事会成员。
- Josh Mandel Brehm,has served as President and Chief Executive Officer of CAMP4 Therapeutics Corporation since May 2017 and as entrepreneur partner with Polaris Partners. Prior to May 2017, Mr. Mandel-Brehm served in business development for Biogen Corporation from May 2013 to May 2017. He has also been a founder and board member for Vico Therapeutics B.V. since October 2019. Mr. Mandel-Brehm earned a Bachelor of Arts degree in Biology from Washington University in St. Louis and a Master of Business Administration from the University of Michigan.
- Neil K. Warma
-
Neil K. Warma先生自2021年5月起担任公司董事。Warma先生已经是一名医疗保健企业家超过25年，管理并为全球众多生物技术和制药公司提供咨询。自2022年4月以来，Warma先生一直担任Genexine，Inc.的总裁兼首席执行官，Genexine是一家公开评级的全球生物制药公司，他还担任该公司董事会成员。此前，Warma先生于2019年9月至2022年5月担任全球生物制药公司I-Mab Biopharma U.S.的总经理。Warma先生是Biohealth Care，LLC的创始人，2018年至2019年担任首席执行官，该公司为医疗保健行业提供咨询服务。此前，Warma先生曾于2008年至2017年担任Opexa Therapeutics，Inc.（一家公开评级的生物制药公司）的总裁兼首席执行官和董事会成员。2004年至2007年，他担任Viron Therapeutics的总裁、首席执行官和董事，在此之前，他曾在瑞士巴塞尔诺华公司担任多个高级职位。Warma先生分别自2021年3月和2020年11月起担任上市公司Genexine Ltd.和生物技术创新组织的董事。Warma先生获得了多伦多大学神经科学学士学位和约克大学工商管理硕士学位。
Neil K. Warma,has served as a director of the Company since May 2021. Mr. Warma has been a healthcare entrepreneur for over 25 years having managed and advised numerous biotechnology and pharmaceutical companies across the globe. Since April 2022, Mr. Warma has been the President and CEO of Genexine, Inc., a publicly-traded global biopharmaceutical company, for which he also serves as a member of its board of directors. Previously, Mr. Warma served as the General Manager of I-Mab Biopharma U.S., a publicly-traded global biopharmaceutical company from September 2019 until May 2022. Mr. Warma was founder and from 2018 to 2019 served as CEO of Biohealth Care, LLC, which provided advisory services to the healthcare industry. Previously, Mr. Warma was President and CEO and a member of the board of directors of Opexa Therapeutics, Inc., a publicly-traded biopharmaceutical company from 2008 to 2017. He was President, CEO and Director of Viron Therapeutics from 2004 to 2007 and prior to that held several senior positions at Novartis AG in Basel, Switzerland. Mr. Warma has served as a director for Genexine Ltd., a public company, and Biotechnology Innovation Organization since March 2021 and November 2020, respectively. Mr. Warma earned a Bachelor of Science degree in Neuroscience from the University of Toronto and a Master of Business Administration from York University. - Neil K. Warma先生自2021年5月起担任公司董事。Warma先生已经是一名医疗保健企业家超过25年，管理并为全球众多生物技术和制药公司提供咨询。自2022年4月以来，Warma先生一直担任Genexine，Inc.的总裁兼首席执行官，Genexine是一家公开评级的全球生物制药公司，他还担任该公司董事会成员。此前，Warma先生于2019年9月至2022年5月担任全球生物制药公司I-Mab Biopharma U.S.的总经理。Warma先生是Biohealth Care，LLC的创始人，2018年至2019年担任首席执行官，该公司为医疗保健行业提供咨询服务。此前，Warma先生曾于2008年至2017年担任Opexa Therapeutics，Inc.（一家公开评级的生物制药公司）的总裁兼首席执行官和董事会成员。2004年至2007年，他担任Viron Therapeutics的总裁、首席执行官和董事，在此之前，他曾在瑞士巴塞尔诺华公司担任多个高级职位。Warma先生分别自2021年3月和2020年11月起担任上市公司Genexine Ltd.和生物技术创新组织的董事。Warma先生获得了多伦多大学神经科学学士学位和约克大学工商管理硕士学位。
- Neil K. Warma,has served as a director of the Company since May 2021. Mr. Warma has been a healthcare entrepreneur for over 25 years having managed and advised numerous biotechnology and pharmaceutical companies across the globe. Since April 2022, Mr. Warma has been the President and CEO of Genexine, Inc., a publicly-traded global biopharmaceutical company, for which he also serves as a member of its board of directors. Previously, Mr. Warma served as the General Manager of I-Mab Biopharma U.S., a publicly-traded global biopharmaceutical company from September 2019 until May 2022. Mr. Warma was founder and from 2018 to 2019 served as CEO of Biohealth Care, LLC, which provided advisory services to the healthcare industry. Previously, Mr. Warma was President and CEO and a member of the board of directors of Opexa Therapeutics, Inc., a publicly-traded biopharmaceutical company from 2008 to 2017. He was President, CEO and Director of Viron Therapeutics from 2004 to 2007 and prior to that held several senior positions at Novartis AG in Basel, Switzerland. Mr. Warma has served as a director for Genexine Ltd., a public company, and Biotechnology Innovation Organization since March 2021 and November 2020, respectively. Mr. Warma earned a Bachelor of Science degree in Neuroscience from the University of Toronto and a Master of Business Administration from York University.
- Maggie Shafmaster
-
Maggie Shafmaster，在为生物技术和制药行业提供知识产权和交易建议方面拥有超过30年的经验。在任职于ProMIS之前，Shafmaster博士于2011年至2014年担任赛诺菲巴斯德的副总裁兼首席专利顾问，并于2006年至2011年担任健赞公司的高级副总裁兼首席专利顾问。她还在商业秘密盗用、专利侵权等诉讼中担任专家证人。Shafmaster博士在康奈尔大学医学科学研究生院获得分子生物学和病毒学博士学位，在纽约法学院获得法学博士学位，在加州大学圣克鲁斯分校获得生物学文学学士学位。
Maggie Shafmaster,has over 30 years of experience providing intellectual property and transactional advice to the biotechnology and pharmaceutical industries. Prior to her tenure at ProMIS, Dr. Shafmaster was Vice President and Chief Patent Counsel at Sanofi Pasteur from 2011 to 2014 and Senior Vice President and Chief Patent Counsel at Genzyme Corp. from 2006 to 2011. She has also acted as an expert witness in litigations involving trade secret misappropriation and patent infringement. Dr. Shafmaster earned her Ph.D. in Molecular Biology and Virology from Cornell University Graduate School of Medical Sciences, a Juris Doctor from New York Law School, and a Bachelor of Arts in Biology from the University of California Santa Cruz. - Maggie Shafmaster，在为生物技术和制药行业提供知识产权和交易建议方面拥有超过30年的经验。在任职于ProMIS之前，Shafmaster博士于2011年至2014年担任赛诺菲巴斯德的副总裁兼首席专利顾问，并于2006年至2011年担任健赞公司的高级副总裁兼首席专利顾问。她还在商业秘密盗用、专利侵权等诉讼中担任专家证人。Shafmaster博士在康奈尔大学医学科学研究生院获得分子生物学和病毒学博士学位，在纽约法学院获得法学博士学位，在加州大学圣克鲁斯分校获得生物学文学学士学位。
- Maggie Shafmaster,has over 30 years of experience providing intellectual property and transactional advice to the biotechnology and pharmaceutical industries. Prior to her tenure at ProMIS, Dr. Shafmaster was Vice President and Chief Patent Counsel at Sanofi Pasteur from 2011 to 2014 and Senior Vice President and Chief Patent Counsel at Genzyme Corp. from 2006 to 2011. She has also acted as an expert witness in litigations involving trade secret misappropriation and patent infringement. Dr. Shafmaster earned her Ph.D. in Molecular Biology and Virology from Cornell University Graduate School of Medical Sciences, a Juris Doctor from New York Law School, and a Bachelor of Arts in Biology from the University of California Santa Cruz.
- Slanix Paul Alex
-
Slanix Paul Alex，2023年加入Ally Bridge Group，担任公共股票策略总裁兼投资组合经理。在加入Ally Bridge Group之前，Alex博士曾作为Tri Locum Partners的创始合伙人和高级分析师投资于生命科学公司。在此之前，Alex博士是Consonance Capital Management的投资分析师，曾在加拿大皇家银行资本市场和瑞士信贷从事卖方生物技术股票研究工作。Alex博士的职业生涯始于Bionest Partners的战略咨询，为生命科学公司提供业务发展和商业战略方面的建议。Alex博士是一名执业药剂师，拥有圣约翰大学的药剂学博士学位。
Slanix Paul Alex,joined Ally Bridge Group in 2023 and is the President and Portfolio Manager for the Public Equity strategy. Before joining Ally Bridge Group, Dr. Alex invested in life sciences companies as a founding Partner and Senior Analyst for Tri Locum Partners. Prior to that, Dr. Alex was an Investment Analyst for Consonance Capital Management and worked in sell-side biotechnology equity research at RBC Capital Markets and Credit Suisse. Dr. Alex began his career in strategy consulting at Bionest Partners, advising life sciences companies on business development and commercial strategy. Dr. Alex is a licensed pharmacist and holds a Pharm.D. from St John's University. - Slanix Paul Alex，2023年加入Ally Bridge Group，担任公共股票策略总裁兼投资组合经理。在加入Ally Bridge Group之前，Alex博士曾作为Tri Locum Partners的创始合伙人和高级分析师投资于生命科学公司。在此之前，Alex博士是Consonance Capital Management的投资分析师，曾在加拿大皇家银行资本市场和瑞士信贷从事卖方生物技术股票研究工作。Alex博士的职业生涯始于Bionest Partners的战略咨询，为生命科学公司提供业务发展和商业战略方面的建议。Alex博士是一名执业药剂师，拥有圣约翰大学的药剂学博士学位。
- Slanix Paul Alex,joined Ally Bridge Group in 2023 and is the President and Portfolio Manager for the Public Equity strategy. Before joining Ally Bridge Group, Dr. Alex invested in life sciences companies as a founding Partner and Senior Analyst for Tri Locum Partners. Prior to that, Dr. Alex was an Investment Analyst for Consonance Capital Management and worked in sell-side biotechnology equity research at RBC Capital Markets and Credit Suisse. Dr. Alex began his career in strategy consulting at Bionest Partners, advising life sciences companies on business development and commercial strategy. Dr. Alex is a licensed pharmacist and holds a Pharm.D. from St John's University.
- William Wyman
-
William Wyman，自2014年3月起担任ProMIS Neurosciences Inc.董事。1984年，Wyman与他人共同创立了Oliver Wyman & Co.，这是一家综合管理咨询公司。自1995年从Oliver Wyman & Co.退休以来，Wyman一直担任金融和科技行业近二十家上市公司和私营公司的董事和顾问。Wyman先生还自2016年起担任Wyman Consulting的顾问和所有者。Wyman先生一直是达特茅斯希区柯克医疗中心、玛丽希区柯克医院和达特茅斯希区柯克诊所的董事会成员，目前是董事会联合发展委员会的成员。他目前是新英格兰学院董事会成员。自2008年起，他担任贸易公司Allston Trading，LLC的董事，并自1995年起担任多家私人股本公司的顾问委员会成员。他还曾在美国国家科学院健康公平委员会任职。
William Wyman,co-founded Oliver Wyman & Co., a general management consulting firm. Since his retirement from the firm in 1995, Mr. Wyman has served as a director and advisor to nearly two dozen public and private companies in the finance and technology industries. Mr. Wyman has also served as a consultant and owner of Wyman Consulting Associates since 2016. Mr. Wyman has been a member of the board of trustees of Dartmouth Hitchcock Medical Center, Mary Hitchcock Hospital, and the Dartmouth Hitchcock Clinic, and currently serves on the Board Joint Development Committee. He is currently a member of the Board of Trustees of New England College. He served as a director of Allston Trading, LLC, a trading firm, since 2008, and as a member of the board of advisors of several private equity firms since 1995. He has also served on the National Academy of Sciences' committee on health equity. Mr. Wyman earned a Bachelor of Arts degree in Economics from Colgate University and a Master of Business Administration from Harvard Business School. - William Wyman，自2014年3月起担任ProMIS Neurosciences Inc.董事。1984年，Wyman与他人共同创立了Oliver Wyman & Co.，这是一家综合管理咨询公司。自1995年从Oliver Wyman & Co.退休以来，Wyman一直担任金融和科技行业近二十家上市公司和私营公司的董事和顾问。Wyman先生还自2016年起担任Wyman Consulting的顾问和所有者。Wyman先生一直是达特茅斯希区柯克医疗中心、玛丽希区柯克医院和达特茅斯希区柯克诊所的董事会成员，目前是董事会联合发展委员会的成员。他目前是新英格兰学院董事会成员。自2008年起，他担任贸易公司Allston Trading，LLC的董事，并自1995年起担任多家私人股本公司的顾问委员会成员。他还曾在美国国家科学院健康公平委员会任职。
- William Wyman,co-founded Oliver Wyman & Co., a general management consulting firm. Since his retirement from the firm in 1995, Mr. Wyman has served as a director and advisor to nearly two dozen public and private companies in the finance and technology industries. Mr. Wyman has also served as a consultant and owner of Wyman Consulting Associates since 2016. Mr. Wyman has been a member of the board of trustees of Dartmouth Hitchcock Medical Center, Mary Hitchcock Hospital, and the Dartmouth Hitchcock Clinic, and currently serves on the Board Joint Development Committee. He is currently a member of the Board of Trustees of New England College. He served as a director of Allston Trading, LLC, a trading firm, since 2008, and as a member of the board of advisors of several private equity firms since 1995. He has also served on the National Academy of Sciences' committee on health equity. Mr. Wyman earned a Bachelor of Arts degree in Economics from Colgate University and a Master of Business Administration from Harvard Business School.
高管简历
中英对照 | 中文 | 英文- Daniel E. Geffken
Daniel E. Geffken自2017年3月起担任CFO。自2011年6月起，他成为Danforth Advisors LLC的联合创始人，并担任董事总经理。Geffken先生还担任Phoenix Biotech Acquisition Corp.、Eloxx Pharmaceuticals，Inc.和OPY Acquisition Corp. I的CFO。Geffken先生曾担任多家上市公司的董事会成员，其中包括Windtree Therapeutics，Inc.，自2019年起担任董事；Arcturus Therapeutics，Inc.，自2017年11月至2018年5月担任董事；Alcobra Pharmaceuticals Inc.，自2013年5月至2017年11月担任董事。Geffken先生自2017年起担任私营公司Elicio Therapeutics的董事会成员。Geffken先生在宾夕法尼亚大学获得经济学学士学位，在哈佛商学院获得工商管理硕士学位。
Daniel E. Geffken was appointed as Interim Chief Financial Officer on April 1, 2021. Mr. Geffken provides all functions required from a chief financial officer, as well as any additional services Eloxx Pharmaceuticals, Inc. may require, under his engagement as a consultant through Danforth Advisors, LLC ("Danforth"). Eloxx Pharmaceuticals, Inc.'s board of directors does not currently plan to appoint a new Chief Financial Officer. He has served as Chief Financial Officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Since 2013, Mr. Geffken has participated in eleven initial public offerings. Mr. Geffken holds a B.S. from The Wharton School, University of Pennsylvania, and an M.B.A. from Harvard Business School.- Daniel E. Geffken自2017年3月起担任CFO。自2011年6月起，他成为Danforth Advisors LLC的联合创始人，并担任董事总经理。Geffken先生还担任Phoenix Biotech Acquisition Corp.、Eloxx Pharmaceuticals，Inc.和OPY Acquisition Corp. I的CFO。Geffken先生曾担任多家上市公司的董事会成员，其中包括Windtree Therapeutics，Inc.，自2019年起担任董事；Arcturus Therapeutics，Inc.，自2017年11月至2018年5月担任董事；Alcobra Pharmaceuticals Inc.，自2013年5月至2017年11月担任董事。Geffken先生自2017年起担任私营公司Elicio Therapeutics的董事会成员。Geffken先生在宾夕法尼亚大学获得经济学学士学位，在哈佛商学院获得工商管理硕士学位。
- Daniel E. Geffken was appointed as Interim Chief Financial Officer on April 1, 2021. Mr. Geffken provides all functions required from a chief financial officer, as well as any additional services Eloxx Pharmaceuticals, Inc. may require, under his engagement as a consultant through Danforth Advisors, LLC ("Danforth"). Eloxx Pharmaceuticals, Inc.'s board of directors does not currently plan to appoint a new Chief Financial Officer. He has served as Chief Financial Officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Since 2013, Mr. Geffken has participated in eleven initial public offerings. Mr. Geffken holds a B.S. from The Wharton School, University of Pennsylvania, and an M.B.A. from Harvard Business School.
- Neil Cashman
Neil Cashman，CSO兼董事Cashman博士分别自2004年5月和2010年6月起担任CSO和公司董事。卡什曼博士从2005年7月起担任英国不列颠哥伦比亚大学教授，直到2022年2月1日成为荣休教授，成为该公司的全职雇员。他还曾于2005年至2019年在加拿大不列颠哥伦比亚大学担任神经退行性疾病和蛋白质错误折叠疾病的加拿大研究主席。2005年7月至2022年1月，他还担任温哥华总医院ALS诊所主任。卡什曼博士在鲍登学院获得物理学学士学位，在马萨诸塞大学医学院获得医学学位。卡什曼博士曾在芝加哥大学医院和诊所担任神经病学住院医师。我们相信Cashman博士在ProMIS Neurosciences Inc.公司的历史经验以及他的专业经验使他有资格担任Promis Neurosciences公司的董事会成员。
Neil Cashman,served as a Professor at the UBC from July 2005 until he became Professor Emeritus as of February 1, 2022, when he became a full-time employee of the Company. He has also served as the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases at UBC from 2005 to 2019. He was also director of the ALS Clinic at Vancouver General Hospital from July 2005 to January 2022. Dr. Cashman earned a Bachelor of Arts degree in Physics from Bowdoin College and a Medical Degree from the University of Massachusetts Medical School. Dr. Cashman served his residency in neurology with the University of Chicago Hospitals & Clinics.- Neil Cashman，CSO兼董事Cashman博士分别自2004年5月和2010年6月起担任CSO和公司董事。卡什曼博士从2005年7月起担任英国不列颠哥伦比亚大学教授，直到2022年2月1日成为荣休教授，成为该公司的全职雇员。他还曾于2005年至2019年在加拿大不列颠哥伦比亚大学担任神经退行性疾病和蛋白质错误折叠疾病的加拿大研究主席。2005年7月至2022年1月，他还担任温哥华总医院ALS诊所主任。卡什曼博士在鲍登学院获得物理学学士学位，在马萨诸塞大学医学院获得医学学位。卡什曼博士曾在芝加哥大学医院和诊所担任神经病学住院医师。我们相信Cashman博士在ProMIS Neurosciences Inc.公司的历史经验以及他的专业经验使他有资格担任Promis Neurosciences公司的董事会成员。
- Neil Cashman,served as a Professor at the UBC from July 2005 until he became Professor Emeritus as of February 1, 2022, when he became a full-time employee of the Company. He has also served as the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases at UBC from 2005 to 2019. He was also director of the ALS Clinic at Vancouver General Hospital from July 2005 to January 2022. Dr. Cashman earned a Bachelor of Arts degree in Physics from Bowdoin College and a Medical Degree from the University of Massachusetts Medical School. Dr. Cashman served his residency in neurology with the University of Chicago Hospitals & Clinics.
- Larry Altstiel
首席营销官Larry Altstiel Altstiel博士自2022年4月起担任公司首席营销官。Altstiel博士在神经退行性疾病方面拥有数十年的医学专长，并在制药行业拥有丰富的经验。自2017年起，Altstiel博士担任Pinteon Therapeutics Inc.的兼职首席医疗官。从2014年至2017年，他担任Neurotrope, Inc.（n/k/a Synaptogenix公司（纳斯达克股票代码：SNPX））的董事和科学顾问。Altstiel博士在伊利诺伊大学获得化学理学学士学位，在洛克菲勒大学获得病毒学博士学位，在迈阿密大学获得医学学位。
Larry Altstiel,has decades of medical expertise in neurodegenerative diseases and experience in the pharmaceutical industry. Since 2017, Dr. Altstiel has served as part-time Chief Medical Officer of Pinteon Therapeutics Inc. From 2014 to 2017, he served as a director and scientific advisor of Neurotrope, Inc. (n/k/a Synaptogenix Inc. (NASDAQ: SNPX)). Dr. Altstiel earned a Bachelor of Science degree in Chemistry from the University of Illinois, a Ph.D. in Virology from the Rockefeller University, and a Medical Degree from the University of Miami.- 首席营销官Larry Altstiel Altstiel博士自2022年4月起担任公司首席营销官。Altstiel博士在神经退行性疾病方面拥有数十年的医学专长，并在制药行业拥有丰富的经验。自2017年起，Altstiel博士担任Pinteon Therapeutics Inc.的兼职首席医疗官。从2014年至2017年，他担任Neurotrope, Inc.（n/k/a Synaptogenix公司（纳斯达克股票代码：SNPX））的董事和科学顾问。Altstiel博士在伊利诺伊大学获得化学理学学士学位，在洛克菲勒大学获得病毒学博士学位，在迈阿密大学获得医学学位。
- Larry Altstiel,has decades of medical expertise in neurodegenerative diseases and experience in the pharmaceutical industry. Since 2017, Dr. Altstiel has served as part-time Chief Medical Officer of Pinteon Therapeutics Inc. From 2014 to 2017, he served as a director and scientific advisor of Neurotrope, Inc. (n/k/a Synaptogenix Inc. (NASDAQ: SNPX)). Dr. Altstiel earned a Bachelor of Science degree in Chemistry from the University of Illinois, a Ph.D. in Virology from the Rockefeller University, and a Medical Degree from the University of Miami.
- Johanne Kaplan
Johanne Kaplan，Kaplan博士自2016年起担任公司首席开发官（“CDO”），并于2022年1月1日开始全职工作。在全职担任CDO之前，卡普兰博士还曾于2016年至2021年担任Shepherd Therapeutics的首席科学官，并于2015年至2016年担任Epiva Biosciences的首席科学官。在加入公司之前，卡普兰博士从1992年至2015年在赛诺菲健赞担任越来越多的职务，最近一次是从2005年起担任赛诺菲健赞研究副总裁，直到2015年退休。作为神经免疫学研究的副总裁，她领导了Genzyme科学团队的贡献，支持Lemtrada（阿仑妥珠单抗）和Aubagio（特立氟胺）用于治疗复发缓解型多发性硬化症的批准。她还建立了伙伴关系，以开发治疗神经炎症性疾病的新疗法。在加入健赞之前，卡普兰博士是SmithKline Beecham的一名助理免疫病理学家，在那里她建立了一个免疫毒理学项目。她的工作已导致70多个科学出版物和多项专利。卡普兰博士拥有加拿大蒙特利尔麦吉尔大学的微生物学和免疫学博士学位，并在纽约的阿尔伯特·爱因斯坦医学院进行博士后研究。
Johanne Kaplan,served as Chief Scientific Officer at Shepherd Therapeutics from 2016 to 2021 and as Chief Scientific Officer at Epiva Biosciences from 2015 to 2016. Before joining the Company, Dr. Kaplan held increasing positions of responsibility at Sanofi Genzyme, from 1992 through 2015, most recently serving as Vice President of Research at Sanofi Genzyme from 2005 until her retirement in 2015. As Vice President of Neuroimmunology Research, she led the contribution of the Genzyme science team supporting the approval of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis. She also established partnerships for the development of novel therapies for neuroinflammatory disorders. Prior to joining Genzyme, Dr. Kaplan was an Associate Immunopathologist at SmithKline Beecham where she established an immunotoxicology program. Her work has resulted in over 70 scientific publications and multiple patents. Dr. Kaplan holds a PhD in Microbiology & Immunology from McGill University in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York.- Johanne Kaplan，Kaplan博士自2016年起担任公司首席开发官（“CDO”），并于2022年1月1日开始全职工作。在全职担任CDO之前，卡普兰博士还曾于2016年至2021年担任Shepherd Therapeutics的首席科学官，并于2015年至2016年担任Epiva Biosciences的首席科学官。在加入公司之前，卡普兰博士从1992年至2015年在赛诺菲健赞担任越来越多的职务，最近一次是从2005年起担任赛诺菲健赞研究副总裁，直到2015年退休。作为神经免疫学研究的副总裁，她领导了Genzyme科学团队的贡献，支持Lemtrada（阿仑妥珠单抗）和Aubagio（特立氟胺）用于治疗复发缓解型多发性硬化症的批准。她还建立了伙伴关系，以开发治疗神经炎症性疾病的新疗法。在加入健赞之前，卡普兰博士是SmithKline Beecham的一名助理免疫病理学家，在那里她建立了一个免疫毒理学项目。她的工作已导致70多个科学出版物和多项专利。卡普兰博士拥有加拿大蒙特利尔麦吉尔大学的微生物学和免疫学博士学位，并在纽约的阿尔伯特·爱因斯坦医学院进行博士后研究。
- Johanne Kaplan,served as Chief Scientific Officer at Shepherd Therapeutics from 2016 to 2021 and as Chief Scientific Officer at Epiva Biosciences from 2015 to 2016. Before joining the Company, Dr. Kaplan held increasing positions of responsibility at Sanofi Genzyme, from 1992 through 2015, most recently serving as Vice President of Research at Sanofi Genzyme from 2005 until her retirement in 2015. As Vice President of Neuroimmunology Research, she led the contribution of the Genzyme science team supporting the approval of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis. She also established partnerships for the development of novel therapies for neuroinflammatory disorders. Prior to joining Genzyme, Dr. Kaplan was an Associate Immunopathologist at SmithKline Beecham where she established an immunotoxicology program. Her work has resulted in over 70 scientific publications and multiple patents. Dr. Kaplan holds a PhD in Microbiology & Immunology from McGill University in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York.
- Neil K. Warma
Neil K. Warma先生自2021年5月起担任公司董事。Warma先生已经是一名医疗保健企业家超过25年，管理并为全球众多生物技术和制药公司提供咨询。自2022年4月以来，Warma先生一直担任Genexine，Inc.的总裁兼首席执行官，Genexine是一家公开评级的全球生物制药公司，他还担任该公司董事会成员。此前，Warma先生于2019年9月至2022年5月担任全球生物制药公司I-Mab Biopharma U.S.的总经理。Warma先生是Biohealth Care，LLC的创始人，2018年至2019年担任首席执行官，该公司为医疗保健行业提供咨询服务。此前，Warma先生曾于2008年至2017年担任Opexa Therapeutics，Inc.（一家公开评级的生物制药公司）的总裁兼首席执行官和董事会成员。2004年至2007年，他担任Viron Therapeutics的总裁、首席执行官和董事，在此之前，他曾在瑞士巴塞尔诺华公司担任多个高级职位。Warma先生分别自2021年3月和2020年11月起担任上市公司Genexine Ltd.和生物技术创新组织的董事。Warma先生获得了多伦多大学神经科学学士学位和约克大学工商管理硕士学位。
Neil K. Warma,has served as a director of the Company since May 2021. Mr. Warma has been a healthcare entrepreneur for over 25 years having managed and advised numerous biotechnology and pharmaceutical companies across the globe. Since April 2022, Mr. Warma has been the President and CEO of Genexine, Inc., a publicly-traded global biopharmaceutical company, for which he also serves as a member of its board of directors. Previously, Mr. Warma served as the General Manager of I-Mab Biopharma U.S., a publicly-traded global biopharmaceutical company from September 2019 until May 2022. Mr. Warma was founder and from 2018 to 2019 served as CEO of Biohealth Care, LLC, which provided advisory services to the healthcare industry. Previously, Mr. Warma was President and CEO and a member of the board of directors of Opexa Therapeutics, Inc., a publicly-traded biopharmaceutical company from 2008 to 2017. He was President, CEO and Director of Viron Therapeutics from 2004 to 2007 and prior to that held several senior positions at Novartis AG in Basel, Switzerland. Mr. Warma has served as a director for Genexine Ltd., a public company, and Biotechnology Innovation Organization since March 2021 and November 2020, respectively. Mr. Warma earned a Bachelor of Science degree in Neuroscience from the University of Toronto and a Master of Business Administration from York University.- Neil K. Warma先生自2021年5月起担任公司董事。Warma先生已经是一名医疗保健企业家超过25年，管理并为全球众多生物技术和制药公司提供咨询。自2022年4月以来，Warma先生一直担任Genexine，Inc.的总裁兼首席执行官，Genexine是一家公开评级的全球生物制药公司，他还担任该公司董事会成员。此前，Warma先生于2019年9月至2022年5月担任全球生物制药公司I-Mab Biopharma U.S.的总经理。Warma先生是Biohealth Care，LLC的创始人，2018年至2019年担任首席执行官，该公司为医疗保健行业提供咨询服务。此前，Warma先生曾于2008年至2017年担任Opexa Therapeutics，Inc.（一家公开评级的生物制药公司）的总裁兼首席执行官和董事会成员。2004年至2007年，他担任Viron Therapeutics的总裁、首席执行官和董事，在此之前，他曾在瑞士巴塞尔诺华公司担任多个高级职位。Warma先生分别自2021年3月和2020年11月起担任上市公司Genexine Ltd.和生物技术创新组织的董事。Warma先生获得了多伦多大学神经科学学士学位和约克大学工商管理硕士学位。
- Neil K. Warma,has served as a director of the Company since May 2021. Mr. Warma has been a healthcare entrepreneur for over 25 years having managed and advised numerous biotechnology and pharmaceutical companies across the globe. Since April 2022, Mr. Warma has been the President and CEO of Genexine, Inc., a publicly-traded global biopharmaceutical company, for which he also serves as a member of its board of directors. Previously, Mr. Warma served as the General Manager of I-Mab Biopharma U.S., a publicly-traded global biopharmaceutical company from September 2019 until May 2022. Mr. Warma was founder and from 2018 to 2019 served as CEO of Biohealth Care, LLC, which provided advisory services to the healthcare industry. Previously, Mr. Warma was President and CEO and a member of the board of directors of Opexa Therapeutics, Inc., a publicly-traded biopharmaceutical company from 2008 to 2017. He was President, CEO and Director of Viron Therapeutics from 2004 to 2007 and prior to that held several senior positions at Novartis AG in Basel, Switzerland. Mr. Warma has served as a director for Genexine Ltd., a public company, and Biotechnology Innovation Organization since March 2021 and November 2020, respectively. Mr. Warma earned a Bachelor of Science degree in Neuroscience from the University of Toronto and a Master of Business Administration from York University.